Home Medizin Sino Biological gibt Dienstleistungspartnerschaft mit Rapid Novor bekannt

Sino Biological gibt Dienstleistungspartnerschaft mit Rapid Novor bekannt

von NFI Redaktion

Sino Biological, Inc. („Sino Biological“), a biotechnology company listed on the Shenzhen Stock Exchange ChiNext, offering biological research reagents and related technical contract research services, is pleased to announce a partnership with Rapid Novor, Inc. („Rapid Novor“) based in Toronto, Canada. Under the terms of this agreement, Sino Biological will market Rapid Novor’s proprietary De novo sequencing service for monoclonal REmAb antibodies in conjunction with its custom mAb development and production services. The geographical areas covered by this partnership include China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, the Philippines, Japan, and South Korea.

Based in Beijing, China, Sino Biological is the world’s leading provider of recombinant proteins, antibodies, and related contract research services based on mammalian cells. A significant portion of its custom contract research services involves the design, development, and manufacturing of custom monoclonal antibodies for basic research and applications in in vitro diagnostics. Providing nucleic acid and amino acid sequence information for the active center of monoclonal antibodies along with the corresponding purified, bioactive antibody to customers will provide invaluable insights into the structure and function of antibodies, allowing customers to optimize antibody engineering strategies, protect intellectual property, expand new diagnostic platforms, and enhance drug research.

Dr. Rob Burgess, Chief Business Officer of Sino Biological, stated: „Rapid Novor’s capabilities in sequencing monoclonal REmAb antibodies perfectly complement Sino Biological’s antibody development and manufacturing services. We believe that combining these services synergistically enhances the value of our customized monoclonal antibody products for our customers.“

„An integrated solution that combines reliable protein sequencing and recombinant expression provides scientists with a convenient way to fully understand and produce useful antibodies,“ explained Iain Rogers, VP Commercial at Rapid Novor. „We are excited that Sino Biological’s customers now have access to accurate sequencing through our REmAb technology.“

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.